Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study
Identifieur interne : 003507 ( PascalFrancis/Checkpoint ); précédent : 003506; suivant : 003508Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study
Auteurs : J.-L. Montastruc [France] ; N. Fabre [France] ; O. Blin [France] ; J.-M. Senard [France] ; Olivier Rascol [France] ; A. Rascol [France]Source :
- Movement disorders [ 0885-3185 ] ; 1995.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Affiliations:
- France
- Midi-Pyrénées
- Marseille, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:95-0362305Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hôp. Rangueil, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Fac. médecine, dep. medical and clin. pharmacology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hôp. Purpan, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">95-0362305</idno><date when="1995">1995</date><idno type="stanalyst">PASCAL 95-0362305 INIST</idno><idno type="RBID">Pascal:95-0362305</idno><idno type="wicri:Area/PascalFrancis/Corpus">003502</idno><idno type="wicri:Area/PascalFrancis/Curation">003322</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hôp. Rangueil, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Fac. médecine, dep. medical and clin. pharmacology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hôp. Purpan, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995">1995</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term><term>Human</term><term>Parkinson disease</term><term>Parkinsonian syndrome</term><term>Previous study</term><term>Toxicity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Fluoxétine</term><term>Antidépresseur</term><term>Parkinson maladie</term><term>Etude préalable</term><term>Toxicité</term><term>Homme</term><term>Parkinsonien syndrome</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>10</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study</s1></fA08><fA11 i1="01" i2="1"><s1>MONTASTRUC (J.-L.)</s1></fA11><fA11 i1="02" i2="1"><s1>FABRE (N.)</s1></fA11><fA11 i1="03" i2="1"><s1>BLIN (O.)</s1></fA11><fA11 i1="04" i2="1"><s1>SENARD (J.-M.)</s1></fA11><fA11 i1="05" i2="1"><s1>RASCOL (O.)</s1></fA11><fA11 i1="06" i2="1"><s1>RASCOL (A.)</s1></fA11><fA14 i1="01"><s1>INSERM Fac. médecine, cent. hosp. univ., dep. medical and clin. pharmacology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>Hôp. Rangueil, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Fac. médecine, dep. medical and clin. pharmacology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Hôp. Purpan, cent. hosp. univ., dep. neurology</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA20><s1>356-357</s1></fA20><fA21><s1>1995</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000050919630240</s5></fA43><fA44><s0>0000</s0></fA44><fA45><s0>16 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>95-0362305</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC02 i1="01" i2="X"><s0>002B02U01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Fluoxétine</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Antidépresseur</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Antidepressant agent</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Antidepresor</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Etude préalable</s0><s5>16</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Previous study</s0><s5>16</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estudio previo</s0><s5>16</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Toxicité</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Toxicity</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="GER"><s0>Giftigkeit</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Toxicidad</s0><s5>17</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Parkinsonien syndrome</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Parkinsonian syndrome</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>45</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>45</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>45</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>46</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>46</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>46</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>47</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>47</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>47</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>48</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>48</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>48</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>49</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>49</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>49</s5></fC07><fN21><s1>205</s1></fN21></pA></standard></inist><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Marseille</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name></noRegion><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003507 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 003507 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:95-0362305
|texte= Does fluoxetine aggravate Parkinson's disease ? A pilot prospective study
}}
| This area was generated with Dilib version V0.6.23. |  |